/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Drug Diaries
  2. Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?
Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Drug Diaries · Aug 29, 2026

Surgeon-scientist Andrew discusses turning cancer into a chronic disease using genomics, liquid biopsies, and long-read sequencing.

Widespread Organoid Adoption Is Blocked by NHS Tissue Handling, Not Technology

The main barrier to using patient-derived organoids (mini-tumor avatars) for personalized treatment isn't the science of growing them. It's the standard NHS practice of immediately fixing biopsy tissue in paraffin, which kills the cells. A system-wide shift to fresh tissue sampling is the critical prerequisite for scale.

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place? thumbnail

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Drug Diaries·3 months ago

Pharma Wastes Potential by Discarding Failed Drugs Without Analyzing Why They Failed

The standard pharmaceutical industry model is to abandon a drug if it fails in trials. A leading scientist argues this is a major flaw. Academic centers can provide the 'proper science' to analyze *why* a drug failed, potentially rescuing valuable compounds or informing future drug design.

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place? thumbnail

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Drug Diaries·3 months ago

Risk-Averse UK Venture Capital Is the Single Biggest Barrier to Commercializing British Science

The UK produces world-class academic discovery but struggles to create scalable biotechs. The primary reason is a lack of venture capital with an appetite for the inherent risks of life sciences, forcing promising UK innovations to move to the US to secure funding.

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place? thumbnail

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Drug Diaries·3 months ago

Cancer Is a Disease of Faulty 'Computer Instructions,' Not Just Uncontrolled Growth

Two people with the same cancer type respond differently to drugs because cancer is driven by accumulating errors in a cell's 'computer code.' A drug might work for one patient but fail in another whose cancer cells have developed an additional 'error' that confers resistance.

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place? thumbnail

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Drug Diaries·3 months ago

A Career-Ending Rejection Can Be the Pivot into Your True Calling

A top surgeon-scientist reveals his academic career began only after being rejected from a surgical training program and told to 'think about giving up.' This catastrophic failure became an unexpected pivot, demonstrating how devastating setbacks can redirect talent toward a more impactful path.

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place? thumbnail

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Drug Diaries·3 months ago

AI's Real Value in Cancer Diagnostics Is Triaging Normal Biopsies

Contrary to hype, AI's most practical current use isn't making complex diagnoses. It's scanning and filtering out the vast number of normal pathology slides. This frees up the limited supply of human pathologists to focus only on abnormal cases, drastically reducing workload and speeding up results.

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place? thumbnail

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Drug Diaries·3 months ago

Long-Read DNA Sequencing Reduces Brain Tumor Diagnosis from 6 Weeks to 15 Minutes

Unlike traditional short-read methods that require days of batch processing, new long-read sequencing technologies like Oxford Nanopore provide real-time data. This allows clinicians to analyze a brain tumor biopsy and determine its specific type in minutes, a process that previously took over a month.

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place? thumbnail

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Drug Diaries·3 months ago

Top Surgeons Carry a 'Graveyard of Their Patients' to Fuel Scientific Breakthroughs

The emotional weight of patient loss isn't just a burden; it's a critical motivator. This 'graveyard' in a surgeon's heart provides the visceral drive to pursue decade-long research in the lab, turning clinical failures into scientific motivation.

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place? thumbnail

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Drug Diaries·3 months ago

The West Midlands' Untapped Advantage for Clinical Trials Is Its Stable, Diverse Population

Unlike transient populations in hubs like London, the West Midlands has a large, ethnically diverse, and stable population. For pharmaceutical companies, this represents an ideal, non-transient cohort—'all the world on their doorstep'—for conducting long-term, representative clinical trials, making it a sleeping giant in life sciences.

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place? thumbnail

Why 90% Of Cancer Treatments Fail – Are We Looking In The Wrong Place?

Drug Diaries·3 months ago